Background: Primary liver tissue cancers display consistent increase in global disease burden 22 and mortality. Identification of cell-of-origins for primary liver cancers would be a necessity 23 to expand options for designing relevant therapeutics and preventive medicine for these cancer 24 types. Previous reports on cell-of-origin for primary liver cancers was mainly from animal 25 studies, and integrative research utilizing human specimen data was poorly established.
for ICCs (Additional file 1: Figure S6a ). Somatic variants of these samples were called from a 114 different method that was designed in each study comparing to the datasets we analyzed. 115 A total of 423 epigenomic data for chromatin feature selections, correlation analyses and COO 116 prediction analyses was obtained from ENCODE (15) and NIH Roadmap Epigenomics 117 Mapping Consortium (16) . NIH Roadmap epigenomics data can be accessed through the NCBI 118 GSE18927 in Gene Expression Omnibus site (https://www.ncbi.nlm.nih.gov/geo/). In addition, 119 chromatin data for liver tissues derived from hepatitis virus infected patients (donor HPC8 and 120 HPC17) was obtained from IHEC (https://epigenomesportal.ca/ihec/download.html).
121
To estimate the regional mutation density and average signal of chromatin features, autosomes 122 were divided into each 1-megabase region except sectors containing low quality unique 123 mappable base pairs, centromeres, and telomeres. 124 We calculated the frequency of somatic mutations and ChIP-seq reads in each 1-megabase 125 region to figure out the regional mutation density and histone modification profiles. The value 126 of DNase I peaks and replication was also used to calculate DNase I hypersensitivity and Repli-127 seq profiles in each 1-megabase region. All these calculations were performed using BEDOPS 128 (17). 152 To predict cell-of-origin (COO) for individual samples, chromatin marks were subgrouped 153 based on the aggregate sample-level feature selection results. As a first step, we selected 154 significant chromatin cell types above the cutoff score from the feature selection results using 155 aggregated samples corresponding to each cancer type (Fig. 1a ). Subsequently, we added 156 relevant cell types and grouped the chromatin marks according to each selected cell type to 157 evaluate the effect of cell-type specific chromatin on explaining variability of mutational 158 landscapes among samples. For predicting the COO for HCCs, we simply utilized the importance ranking among variables from 423 chromatin features due to the fact that liver 160 chromatin features were the only major type in the aggregated feature selection results for 161 HCCs.
Prediction of cell-of-origin by grouping of chromatin features

163
Signature analysis of mutational processes 164 Nonnegative matrix factorization (NMF) algorithm was employed to investigate mutation 165 signatures as described in previous study (19) . This methodology was utilized by factoring out 166 frequency matrix of 96-trinucleotide mutation contexts from HCC, Mixed, ICC, BTCA-SG 167 and HPC samples. between hepatocytic-and non-hepatocytic-origin HCCs was analyzed using limma-voom 175 v3. 26.9 (20) . Gene set enrichment analysis (GSEA) was performed using the GSEAPreranked 176 v5 module on the GenePattern server (https://genepattern.broadinstitute.org).
Results
182
Aggregate Sample-level Correlations Between Chromatin Marks and Somatic Mutations
of PLCs
184
Based on the previous findings about the close associations between the chromatin feature 185 levels and regional variations in somatic mutation frequencies of tumor (18) and a number of 186 precancerous lesions (21), we first hypothesized that the whole-genome mutation landscape of 187 hepatocytic PLC subtype (HCCs) would exhibit closer relationship with the liver tissue 188 (surrogate tissue for the hepatocytes) chromatin marks, whereas the mutation landscape of 189 partial or fully biliary PLC subtypes (Mixed and ICCs) and the BTCAs would likely to display 190 higher correlations with the chromatin marks from tissues containing either cuboidal or 191 columnar epithelium (kidney, stomach or intestines as representative surrogate tissues for the 192 cholangiocytes), depending on the extent of biliary phenotype and anatomical location. To 193 examine differential associations among the mutation landscape for different subtypes of PLCs 194 and the chromatin feature levels from normal tissues, we first employed a random-forest based 195 feature selection method to identify the chromatin features responsible for explaining the 196 possible variances in regional somatic mutation frequencies. To conduct the analysis, we 197 utilized the 1-megabase window somatic mutation frequency data for three subtypes of PLCs 198 (HCCs, Mixed and ICCs) and BTCAs at an aggregated sample level along with the 1-megabase 199 window chromatin feature counts. As hypothesized, liver tissue chromatin marks served as 200 major features with significance for HCCs, and stomach tissue chromatin mark served as the 201 first-rank feature for ICCs and BTCAs (P < 2.2e-16, Mann-Whitney U-test between the first-202 and second-rank features of each PLC subtype; Fig. 1a) . Surprisingly, liver tissue chromatin 203 marks were major features explaining the regional mutation variation of Mixed albeit 204 containing the biliary phenotype, implicating the unexpected skewness of possible COO towards to the hepatocytes for the particular subtype. The lower variance explained score for 206 Mixed and ICCs comparing to the HCCs were at least in part likely due to the lower number 207 of the samples and the total mutation load (Additional file 1: Figure S1a , b), indicating that the 208 correlation between the liver tissue chromatin feature levels and the somatic mutation 209 landscape of Mixed is similar to that of HCCs. In line with these result, spearman correlations 210 between the regional mutation frequency of HCCs or Mixed and liver H3K4me1 chromatin 211 mark level was the highest among different possible surrogate tissues, whereas stomach 212 H3K4me1 chromatin mark level showed the highest correlation with the regional mutation 213 frequency of BTCAs. (Additional file 1: Figure S2a , b). Spearman correlation values among 214 the regional mutation frequency of ICCs and H3K4me1 of different tissues were overall low 215 without any particular tissue type dependent differences, possibly due to both the lower 216 mutation load and the possible variability in COOs which have been previously reported (12).
217
Similar to the spearman correlation results, regional quintile-based mean mutation density data Alongside with these result, principle coordinate analysis (PCOA) result revealed that the PLCs 248 with hepatocytic predicted COO tend to aggregate as a cluster with all of the samples displaying 249 principle coordinate 1 value over 0 (Additional file 1: Figure S4 ). In terms of the PLC subtypes,
250
HCCs and Mixed samples were all contained within a cluster except for the ones with non-251 hepatocytic predicted COOs, whereas the ICCs and BTCAs were more spread out ( Fig. 2b) , 252 reflecting the distinct mutation landscape patterns.
To demonstrate whether HCCs with non-hepatocytic predicted COO have a unique phenotype 254 compared to the hepatocyte-origin HCCs, we analyzed the gene expression profiles. Among 255 the non-hepatocytic-and hepatocyte-origin predicted HCC samples, tumor RNA-Seq data were 256 available for 6 and 189 samples, respectively (4). A comparison of gene expression levels 257 between them showed that 124 genes were up-regulated and 21 genes were down-regulated in 258 non-liver-origin HCCs (FDR < 0.05, absolute logFC > 0.647; Additional file 1: Table S1 ).
259
Interestingly, the upregulated genes included an epithelial cell marker EPCAM and a 260 cholangiocyte-specific marker KRT19 (Fig. 2c ). Clustering analysis confirmed that HCCs with 261 non-hepatocytic predicted COO were enriched in a cluster that expressed more EPCAM and 262 KRT19 (Fig. 2d ). Gene set enrichment analysis showed that molecular pathways associated 263 with bile acid synthesis, xenobiotic degradation, and hepatocyte nuclear factor were down-264 regulated in HCCs with non-hepatocytic predicted COO (Additional file 1: Figure S5 ). This 265 result indicates that the functional similarity to hepatocyte was lower in HCCs with non-266 hepatocytic predicted COO compared to hepatocyte-origin HCCs. Collectively, mRNA 267 expression in non-hepatocyte-origin predicted HCCs partly resembled that of biliary epithelial 268 cells. We also compared hepatocyte-and non-hepatocyte-origin predicted HCCs in terms of 269 clinical features (including tumor stage and survival), but we did not see statistically significant 270 difference in these features, implying that the COO assignments for HCCs might be 271 independent from the clinical prognosis. HCV-infected liver tissues, thus ensuring more relevancy (Additional file 1: Table S2 ). In line 288 with these results, variance explained scores for the ICCs calculated by using a total of 9 cell 289 or tissue types, we discovered that the chromatin features with the highest level of variance 290 explained scores were derived from different tissues depending on the hepatitis infection status 291 of ICCs (HBV = kidney tissue, HCV = liver tissue, NBNC = stomach tissue) (Additional file 292 1: Figure S6b ). Albeit limited number of virus infected ICC samples, our results implicate a 293 potential skewness of COO depending on the virus infection status, and a separate cohort level 294 study with larger number of samples is strongly warranted. In addition, these results also 295 reflects the previous findings in differential infectivity of HBVs and HCVs for cholangiocytes 296 (22, 23). rank chromatin feature and the total 423 features were either below 0 or 25% (Fig. 3a) . In 307 contrast, mutation frequency data of colon stem cells (14) (counterpart stem cell type) at an 308 aggregate sample level were explained by pre-existing set of chromatin features with variance 309 explained score over 40% for the H3K9me3 rectal mucosa mark and over 60% for the total 423 310 features. Post-adjustment of mutation load for colon stem cells at the level of HPCs still showed 311 chromatin marks derived from the rectal mucosa tissue as a top rank feature with over 28% 312 variance explained score, implicating that the differential mutation load might not be a 313 contributing factor for the distinct feature selection analysis results. These results infer distinct 314 mutation landscape between the HPCs and other PLCs, and thus points out the possibility that 315 HPCs might not be a direct COO of PLCs.
316
Mutation signature analysis on the somatic mutation landscape of HPCs were previously 317 performed, and identified a specific age-associated mutation signature displaying correlation 318 with the replication timing and the average chromatin level of cell lines registered in the 319 ENCODE project (14). Based on these findings, we conducted the mutation signature analysis 320 on the HPCs along with the PLCs and BTCAs. As predicted, we successfully extracted a 321 resembling signature (signature D) to the age-associated signature previously identified in the 322 HPCs with similar relative proportion level, along with the other three mutation signatures 323 (Additional file 1: Figure S7a, b ). Next, we assessed whether the proportion of signature D is 324 correlating with the COO assignment for PLCs. As demonstrated in Fig. 3b , relative contribution level of signature D was significantly lower for non-hepatocytic predicted COO Several recent studies support the idea of chromatin marks serving as a crucial factor in shaping chromatin marks may infer the distinctiveness of chromatin landscape between the 374 differentiated cells/tissues and the progenitor/stem cells. Although we cannot fully reject the 375 possibility that the HPCs are still the very first COO of PLCs, our results at least suggest that 376 the major somatic mutation accumulation would most likely to happen on differentiated cells, 377 not at the progenitor/stem cell level. Future assessment on the relationship between the 378 chromatin marks derived from the HPCs and the mutational landscape of PLCs and HPCs 379 might be a separate confirmatory study, although the limitation on the number of 380 progenitor/stem cells directly from human liver and its purity are major hurdles for ChIP-seq 381 or any other epigenomics assays to be performed. 
